Poly(allylamine)/tripolyphosphate nanocomplex coacervate as a NLRP3-dependent systemic adjuvant for vaccine
Biorxiv : the Preprint Server for Biology
|July 15, 2024
Summary
Functional nanoparticles enhance immune responses for vaccines. These poly(allylamine hydrochloride)/tripolyphosphate nanoparticles activate immune cells and promote a Th1-dependent response, showing promise for new vaccine formulations.
Area of Science:
- Nanomedicine
- Immunology
- Vaccinology
Background:
- Nanoparticles (NPs) are key in vaccine development, serving as antigen carriers and adjuvants.
- Complex coacervate-like NPs offer potential as safe and effective vaccine vehicles.
Purpose of the Study:
- To evaluate poly(allylamine hydrochloride)/tripolyphosphate (PAH/TPP) NPs as a systemic vaccine vehicle and adjuvant.
- To investigate NP activation of antigen-presenting cells (APCs) and their adjuvanticity.
Main Methods:
- In vitro co-incubation of APCs with NPs, LPS, and inhibitors.
- In vivo immunization of mice with NP-OVA (ovalbumin).
- Analysis of APC activation markers (CD86, MHCII), cytokine production (IL-1β, IL-18, IFN-γ), and antibody responses (IgG, IgG2a).
Main Results:
- NPs increased APC activation markers and promoted IL-1β and IL-18 secretion via NLRP3 inflammasome and autophagy.
- Systemic NP-OVA administration induced robust OVA-specific IgG and IgG2a, increased IFN-γ, and generated Th1-biased CD4+ and CD8+ T cell responses.
- PAH/TPP NPs demonstrated Th1-dependent adjuvant properties.
Conclusions:
- PAH/TPP NPs activate innate immune cells through inflammasome and autophagy pathways.
- These NPs possess significant Th1-dependent adjuvant properties, suitable for novel vaccine formulations.
- The findings support the use of these NPs for developing vaccines against infectious and non-infectious diseases.
